Graft Versus Host Disease Clinical Trial
Official title:
The Affect of Radiated Versus Non-Irradiated Blood on Extracellular Potassium Levels in Infants Undergoing Craniosynostosis Repair
NCT number | NCT02483702 |
Other study ID # | 15-063 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 2015 |
Est. completion date | May 11, 2017 |
Verified date | October 2018 |
Source | Valley Anesthesiology Consultants |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Blood transfusions are required for patients undergoing a craniosynostosis repair due to the
significant amount of blood loss. Irradiated or non-irradiated transfusions have many risks
involved including elevated potassium levels and graft versus host disease (TA-GVHD).
Irradiated blood is able to destroy the leukocytes responsible for TA-GVHD, but it adversely
causes elevated extracellular potassium due to hemolysis of the RBC's. When this blood is
transfused, it may introduce too much extracellular potassium (> 6.5 meq/L) into the patient
causing interference with the heart's conduction system significantly increasing the risk for
hemodynamic changes, cardiac arrhythmias, and cardiac arrest. Hyperkalemia from rapid
transfusions occurs much more frequently than TA-GVHD; however, both complications are
under-reported.
The study aims to evaluate the risk of irradiated versus non-irradiated blood in patients
under the age of 6 months undergoing a craniosynostosis repair. This will be done by
comparing the levels of extracellular potassium pre-transfusion, during transfusion,
immediately after transfusion, and 30 minutes after the completion of transfusion. The
investigators hypothesize that the patients who receive irradiated blood will have an
increased extracellular potassium level compared to those who receive non-irradiated blood.
Status | Completed |
Enrollment | 20 |
Est. completion date | May 11, 2017 |
Est. primary completion date | May 11, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 2 Months to 6 Months |
Eligibility |
Inclusion Criteria: - Must be between 2-6 m/o - Must be undergoing a craniosynostosis repair - Must require a blood transfusion Exclusion Criteria: |
Country | Name | City | State |
---|---|---|---|
United States | Phoenix Children's Hospital | Phoenix | Arizona |
Lead Sponsor | Collaborator |
---|---|
Valley Anesthesiology Consultants |
United States,
Bontadini A, Tazzari PL, Manfroi S, Tassi C, Conte R. Apoptosis in leucodepleted packed red blood cells. Vox Sang. 2002 Jul;83(1):35-41. — View Citation
Faberowski LW, Black S, Mickle JP. Blood loss and transfusion practice in the perioperative management of craniosynostosis repair. J Neurosurg Anesthesiol. 1999 Jul;11(3):167-72. — View Citation
Lee AC, Reduque LL, Luban NL, Ness PM, Anton B, Heitmiller ES. Transfusion-associated hyperkalemic cardiac arrest in pediatric patients receiving massive transfusion. Transfusion. 2014 Jan;54(1):244-54. doi: 10.1111/trf.12192. Epub 2013 Apr 15. Review. — View Citation
Olson J, Talekar M, Sachdev M, Castellani W, De la Cruz N, Davis J, Liao J, George M. Potassium changes associated with blood transfusion in pediatric patients. Am J Clin Pathol. 2013 Jun;139(6):800-5. doi: 10.1309/AJCP2MP8OIIXNKXF. — View Citation
Rosen NR, Weidner JG, Boldt HD, Rosen DS. Prevention of transfusion-associated graft-versus-host disease: selection of an adequate dose of gamma radiation. Transfusion. 1993 Feb;33(2):125-7. — View Citation
Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Haematol. 2002 May;117(2):275-87. Review. — View Citation
Sharma S, Sharma P, Tyler LN. Transfusion of blood and blood products: indications and complications. Am Fam Physician. 2011 Mar 15;83(6):719-24. Review. — View Citation
Vraets A, Lin Y, Callum JL. Transfusion-associated hyperkalemia. Transfus Med Rev. 2011 Jul;25(3):184-96. doi: 10.1016/j.tmrv.2011.01.006. Epub 2011 Apr 17. Review. — View Citation
Weiskopf RB, Schnapp S, Rouine-Rapp K, Bostrom A, Toy P. Extracellular potassium concentrations in red blood cell suspensions after irradiation and washing. Transfusion. 2005 Aug;45(8):1295-301. Erratum in: Transfusion. 2006 Aug;46(8):1461. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in extracellular potassium values. | We hope to determine if irradiated blood will pose a greater risk for hyperkalemia than non-irradiated blood products. This will be done by looking at potassium values immediately after transfusion and again 30 minutes after the end of transfusion. | immediately after transfusion and 30 minutes after the end of transfusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03357159 -
Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Recruiting |
NCT01385124 -
Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01616680 -
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease
|
Phase 2 | |
Recruiting |
NCT01810926 -
T&B Depletion Non Malignant
|
Phase 2 | |
Completed |
NCT01379209 -
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
|
Phase 1/Phase 2 | |
Completed |
NCT01233921 -
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
|
N/A | |
Recruiting |
NCT00986557 -
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
|
Phase 2 | |
Enrolling by invitation |
NCT00972660 -
Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease
|
Phase 2 | |
Terminated |
NCT00555048 -
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT00373815 -
Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease
|
Phase 1 | |
Terminated |
NCT00608517 -
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
|
N/A | |
Completed |
NCT00056875 -
Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants
|
Phase 1/Phase 2 | |
Recruiting |
NCT05808985 -
Intestinal Microbiome-based Research for the Prevention of Acute GVHD
|
Phase 2 | |
Completed |
NCT00813618 -
Study of MEDI 507 in the Treatment of Pediatric Patients
|
Phase 1 | |
Completed |
NCT00003398 -
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
|
Phase 4 | |
Terminated |
NCT00005641 -
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
|
Phase 2 | |
Completed |
NCT02663622 -
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
|
Phase 2 | |
Completed |
NCT00577278 -
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
|
Phase 2 |